Through trusted collaborations with global pharmaceutical partners — including Teva, Sandoz, Cipla, Dr. Reddy’s, STADA, and other reliable companies — Lotus expands its reach to more markets while strengthening its portfolio across complex generics, particularly in Oncology & Immunology and Central Nervous System therapeutic areas, as well as branded drugs, 505(b)(2) formulations, biosimilars, and NCEs. These partnerships help broaden access to important therapies and enhance the value we deliver to patients worldwide.
Global Partnerships
Core Business
We strengthen our portfolio through product acquisitions and global licensing partnerships, encompassing in-licensing of external innovations and out-licensing of our in-house developed and manufactured products. These strategic collaborations expand our market reach and support sustained growth, enhancing our ability to deliver quality-assured solutions across diverse therapeutic areas.
In-Licensing Business
Out-Licensing Business
Through strong partnerships, we have built a diverse and expanding product portfolio for the Asian market, spanning generics, branded drugs, biosimilars, NCEs, and 505(b)(2) products. Our strategic focus centers on five key therapeutic areas—Oncology & Immunology, Central Nervous System, Primary Care & Lifestyle, Women’s Healthcare, and Nephrology. If you are interested in exploring in-licensing opportunities, please contact our BD team at: BD@@lotuspharm.com
